ClinicalTrials.gg
RecruitingNCT07170475iFRESH-PDUpdated Sep 12, 2025

A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease

A Phase 1 interventional study of Febuxostat and Inosine in Parkinson's Disease (PD), sponsored by Fujita Health University. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Fujita Health University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Parkinson Disease with a site in Japan — 9 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Japan.

Planned enrollment
49th of 60
24 · median 99
Started
2025
with 1 other
Phase 1
13 of 75
4 open now
Registered
72nd of 75
by date

Among the 75 studies in Parkinson Disease with a site in Japan, this one is the 49th largest by planned enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2025, is one of 13 in phase 1, and was the 72nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

9 of the 75 studies in Parkinson Disease with a site in Japan are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Parkinson Disease with a site in Japan, or all of them as a file.
02

Study summary

This study will test the safety of twice-daily oral dosing of combined febuxostat and inosine in 24 patients with Parkinson's disease. Participants will receive one of the four regimens, taken twice daily for 12 weeks:

Who can join: Adults with early-stage Parkinson's disease on stable medication regimens.

What participants do:

  • Take their assigned dose twice daily (morning and evening) for 12 weeks.
  • Visit the clinic at baseline and weeks 4, 8, and 12 for blood tests (including hypoxanthine), exams, and questionnaires.
  • Keep a simple diary of any side effects or changes in daily activities.

Risks and benefits: Possible side effects include mild gastrointestinal upset, headache, or elevated uric acid levels. While direct benefit is not guaranteed, this safety data will inform future Parkinson's disease treatments.

Learn more: Contact [site-specific contact info] for details on eligibility and enrollment.

03

Conditions studied

  • Parkinson's Disease (PD)

Browse trials for

Keywords

  • Parkinson Disease
  • Febuxostat
  • Inosine
  • Hypoxanthine
  • Combination Therapy
  • Safety Study
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide voluntary written .
  2. Receiving stable Parkinson's disease medication (no changes in type or dose) for at least 3 months before enrollment.
  3. Age 18 to 80 years at the time of consent.
  4. Diagnosed with Parkinson's disease by a specialist according to MDS-PD diagnostic criteria, and at pre-enrollment screening, all of the following are met:

    1. Hoehn-Yahr stage (ON state) 1 to 3
    2. MDS-UPDRS Part III (ON state) score 10 to 35
    3. (MMSE) score ≥ 24

Exclusion criteria

Exclusion Criteria:

  1. Requires almost total assistance in daily life and is unable to walk or stand unaided.
  2. Currently taking azathioprine, mercaptopurine hydrate, vidarabine, didanosine, or rosuvastatin.
  3. Used febuxostat, allopurinol, or topiroxostat within 3 months before study start.
  4. Taking any supplement containing inosine.
  5. Started any new Parkinson's disease medication or therapy within 3 months before enrollment.
  6. Serum creatinine >1.5× (ULN), or (GOT) or ALT (GPT) >2× ULN at screening.
  7. History of surgical treatment for Parkinson's disease.
  8. History of or comorbid /allergy to any ingredient of the drugs.
  9. Participation in another clinical trial involving an unapproved drug within 30 days before consent, or currently enrolled in another interventional study.
  10. Pregnant or breastfeeding, or unwilling/unable to use reliable during the study period.
  11. Positive test at screening for , , HTLV-1, or syphilis; ** antibody-positive with undetectable HCV RNA** is allowed.
  12. Unable to take the investigational drugs orally without changing the dosage form.
  13. Gastrointestinal disease or prior GI surgery that may affect drug absorption, as judged by the investigator.
  14. Psychiatric disorder or symptoms that interfere with daily life and make study participation difficult.
  15. Unable to complete assessments or questionnaires independently.
  16. Any other condition that, in the investigator's judgment, would make participation unsafe or inappropriate.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Group 1 - Febuxostat + Inosine (Dose Level 1)

    Participants receive febuxostat and inosine (Dose Level 1) orally, twice daily (once in the morning and once in the evening) for 12 weeks.

    Drug: Febuxostat · Drug: Inosine

  • Experimental
    Group 2 - Febuxostat + Inosine (Dose Level 2)

    Participants receive febuxostat and inosine (Dose Level 2) orally, twice daily (once in the morning and once in the evening) for 12 weeks.

    Drug: Febuxostat · Drug: Inosine

  • Experimental
    Group 3 - Febuxostat + Inosine (Dose Level 3)

    Participants receive febuxostat and inosine (Dose Level 3) orally, twice daily (once in the morning and once in the evening) for 12 weeks.

    Drug: Febuxostat · Drug: Inosine

  • Experimental
    Group 4 - Febuxostat + Inosine (Dose Level 4)

    Participants receive febuxostat and inosine (Dose level 4) orally, twice daily (once in the morning and once in the evening) for 12 weeks.

    Drug: Febuxostat · Drug: Inosine

Interventions

  • Febuxostat tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.

  • Inosine tablets (per randomized assignment), administered orally twice daily (once in the morning and once in the evening) for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in plasma hypoxanthine concentration from baseline to Week 12

    The difference in plasma hypoxanthine level (µmol/L) between pre-dose at Day 0 and Week 12 visit.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in plasma hypoxanthine concentration from baseline to Week 4

    The difference in plasma hypoxanthine level between pre-dose at Day 0 and Week 4 visit.

    Time frame: 4 weeks

  2. Change in cerebrospinal fluid (CSF) hypoxanthine concentration from baseline to Week 12

    The difference in CSF hypoxanthine level between the pre-dose at Day 0 and the Week 12 visit.

    Time frame: 12 weeks

  3. Change in MDS-UPDRS Part III score from baseline to Week 12

    The difference in Movement Disorder Society-Unified Parkinson's Disease Rating Scale motor examination (ON state) score between Day 0 and Week 12.

    Time frame: 12 weeks

  4. Change in Mini-Mental State Examination (MMSE) score from baseline to Week 12

    The difference in MMSE score between Day 0 and Week 12.

    Time frame: 12 weeks

  5. Change in Geriatric Depression Scale-15 (GDS-15) score from baseline to Week 12

    The difference in GDS-15 score between Day 0 and Week 12.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kamatani N, Hashimoto M, Sakurai K, Gokita K, Yoshihara J, Sekine M, Mochii M, Fukuuchi T, Yamaoka N, Kaneko K. Clinical studies on changes in purine compounds in blood and urine by the simultaneous administration of febuxostat and inosine, or by single administration of each. Gout and Nucleic Acid Metabolism. 2017;41 (2): 171-181.
  • Kamatani N, Kushiyama A, Toyo-Oka L, Toyo-Oka T. Treatment of two mitochondrial disease patients with a combination of febuxostat and inosine that enhances cellular ATP. J Hum Genet. 2019 Apr;64(4):351-353. doi: 10.1038/s10038-018-0558-0. Epub 2019 Jan 10. PubMed 30631120 ↗
  • Johnson TA, Jinnah HA, Kamatani N. Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP. Front Pharmacol. 2019 Feb 19;10:98. doi: 10.3389/fphar.2019.00098. eCollection 2019. PubMed 30837873 ↗
  • Shima S, Mizutani Y, Yoshimoto J, Maeda Y, Ohdake R, Nagao R, Maeda T, Higashi A, Ueda A, Ito M, Mutoh T, Watanabe H. Uric acid and alterations of purine recycling disorders in Parkinson's disease: a cross-sectional study. NPJ Parkinsons Dis. 2024 Sep 9;10(1):170. doi: 10.1038/s41531-024-00785-0. PubMed 39251680 ↗
  • Watanabe H, Hattori T, Kume A, Misu K, Ito T, Koike Y, Johnson TA, Kamitsuji S, Kamatani N, Sobue G. Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine. Medicine (Baltimore). 2020 Aug 28;99(35):e21576. doi: 10.1097/MD.0000000000021576. PubMed 32871874 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (including the dataset and data dictionary) and the whole study protocol will be made available to qualified researchers beginning 6 months after publication and ending 3 years after publication. Requests should be directed to the corresponding author, Dr. Hirohisa Watanabe (email: hirohisa.watanabe@fujita-hu.ac.jp), with a research proposal and data use agreement. IPD Sharing Time Frame: Available 6 months to 3 years after publication. IPD Sharing Access Criteria: Qualified researchers with IRB/ethics approval and a signed data use agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Available 6 months to 3 years after publication of the primary results.

Access criteria: Qualified researchers who have obtained approval from their institutional review board or ethics committee and who sign a data use agreement with the study sponsor may request access to de-identified individual participant data, the full study protocol, statistical analysis plan, informed consent form, and analytic code. Requests should be submitted via email to the corresponding author, Dr. Hirohisa Watanabe (hirohisa.watanabe@fujita-hu.ac.jp), and include a brief research proposal and evidence of IRB/ethics approval.

Data sharing details ↗ · jrct.mhlw.go.jp

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2026, 9 months after the start.

Of 77 non-industry phase 1 interventional studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 9 months is below that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2025
First posted
Sep 12, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07170475
Lead sponsor
Fujita Health University
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Jun 27, 2025
Primary completion
Mar 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Sep 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Febuxostat · Inosine

Start the discussion